Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Maybe kly management don’t want to attract another company s

<< Previous

Bullboard Posts

Next >>

Comment by Theknocker91on Apr 24, 2020 8:24pm

65 Views

Post# 30952216

RE:RE:Maybe kly management don’t want to attract another company s

Hey Jack, maybe you should check the stock price history of companies that bassa has ran, then you'll see why there was a share dump when the acquisition was announced. I'm sure he made money, but shareholders didnt. Kaly has no business acquiring another company right now, shareholders have lost enough already. A partnership or licensing deal needs to happen. The optimist in me believes that companies were lowballing kaly so kaly announced that acquisition as a bluff to say "well we'll do it this way then if you won't play ball".

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects